BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated ...

European Commission grants marketing approval for Eylea 8 mg to treat macular edema following RVO, including branch, central and hemiretinal vein occlusion: Berlin Monday, January ...

Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...

Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

Real-world, 12-month results demonstrated efficacy, safety and durability for faricimab as a treatment for retinal vein ...

NovaBridge as we executed a new business strategy and built a truly global platform. This, combined with compelling Phase 1b ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...

The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...

Type 1 diabetes is a chronic autoimmune condition affecting over 9 million people worldwide, caused by the body's immune system attacking the insulin-producing cells in the pancreas, resulting in high ...

Panelists discuss how identifying candidates for anti-amyloid therapy requires precise evaluation of disease stage, cognitive ...